Pomerantz Law Firm Announces the Filing of a Class Action Against AeroVironment, Inc. and Certain Officers

AeroVironment (AVAV) faces a securities class action filed over alleged misstatements regarding its SCAR program (BlueHalo/BADGER). During the Class Period, shares fell sharply on multiple SCAR-related setbacks—down 15.77% ($61.97) to $330.89 on Jan. 20, 2026 after a stop-work order, then down 17.42% ($43.93) to $208.32 on Mar. 2 after reports of SCAR reassessment, and down 6.24% ($13.84) to $207.73 on Mar. 11 after its Q3 FY2026 results. The company reported a Q3 FY2026 operating loss of $179.0M (vs. $3.1M prior year) including a $151.3M goodwill impairment tied to the BADGER stop-work/contract termination and said it would need to recompete for SCAR.

Analysis

This is less a litigation story than a rerating of AVAV’s space thesis from “sticky, high-growth sole-source program” to “competitive, price-sensitive procurement.” Once a customer signals it wants commercial off-the-shelf alternatives, the implied terminal economics on the acquired space platform compress: lower gross margin, less visibility, and a higher chance the BlueHalo purchase price gets remembered as over-earning for a contract that was never truly captive. That matters more than the lawsuit itself because it changes the market from valuing a growth compounder to underwriting a contested bid stream.

Near term, the stock can still drift lower on disclosure risk if investors infer there may be more impairment, contract concentration, or integration surprises buried in the next filing. The next 1-3 months are about whether management can replace lost SCAR revenue with credible pipeline data; absent that, the market will likely apply a “one-off franchise” discount to the space segment and a lower multiple to the whole company. Over 6-18 months, the issue is structural: a procurement regime that favors modular, cheaper solutions will pressure AVAV’s pricing power and could also force competitors to sharpen bids across adjacent defense tech competitions.

The contrarian view is that the litigation headline itself is probably not the main incremental driver; much of the easy downside already came from the stop-work/termination sequence. What remains underappreciated is that the thesis break is operational, not legal: if SCAR-like programs migrate toward multi-vendor sourcing, AVAV’s rebound is capped even if the lawsuit is dismissed. Falsifier: a new Space Force award structure that restores sole-source economics, or management printing meaningful space backlog/book-to-bill without fresh write-downs.

Key Decisions for Investors

• Short AVAV on any relief rally over the next 1-2 weeks; use the recent contract-reset as the real thesis driver, not the lawsuit. Risk/reward is favorable if the market still prices in a meaningful SCAR rebound that now looks structurally unlikely.
• Buy AVAV put spreads 2-4 months out rather than outright puts to limit event-decay risk; target strikes around the post-drop trading range and use them as a hedge into earnings or any amended contract disclosure.
• Relative-value pair: long ITA or LHX vs short AVAV for 1-3 months. The basket hedge dampens sector beta while expressing that AVAV has the most idiosyncratic procurement and margin reset risk.
• Set an alert for any Space Force award language that explicitly mentions multi-vendor or COTS procurement. If that language appears, cover aggressively; if not, treat each bounce as a sellable event.